公开(公告)号：US20230348586A1

公开(公告)日：2023-11-02

申请号：US18026696

申请日：2021-09-21

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Phillipp E. SCHERER ,  Shangang ZHAO ,  Zhiqiang AN ,  Ningyan ZHANG

IPC: C07K16/26 ,  A61K38/46 ,  A61K31/7088 ,  A61K38/22 ,  C12N15/113 ,  A61K38/26 ,  A61K39/395 ,  A61P3/04 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P1/16

CPC classification number: C07K16/26 ,  A61K38/465 ,  A61K31/7088 ,  A61K38/2264 ,  C12N15/1136 ,  A61K38/26 ,  A61K39/3955 ,  A61P3/04 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P1/16 ,  C12N2310/14 ,  C12N2310/531 ,  A61K2039/505

Abstract: The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.